Introduction
============

Atherogenesis is a chronic inflammatory process that involves a complex interplay between circulating cellular and blood elements and the cells of the arterial wall.[@b1-vhrm-7-333],[@b2-vhrm-7-333] While many factors are involved, the "oxidation hypothesis" has been a central focus in the investigation of the pathogenesis of the atherosclerotic process, suggesting that the oxidative modification of low-density lipoprotein (LDL), or other lipoproteins, is central, if not obligatory for the atherogenic process.[@b3-vhrm-7-333],[@b4-vhrm-7-333]

Oxidation of LDL is a lipid peroxidation process resulting in formation of a wide range of biologically active products, including peroxides and malondialdehyde. Oxidation of LDL results in the generation of aldehydes that substitute lysine residues in the apoprotein B-100 moiety of LDL and causes apolipoprotein B-100 fragmentation. As a result, the particle loses its affinity for the LDL receptor and binds avidly to scavenger receptors on macrophages, resulting in foam cell formation.[@b5-vhrm-7-333],[@b6-vhrm-7-333]

Advances in the management of hypercholesterolemia are primarily due to the development of the 3-hydroxy-3-methylglutaryl coenzyme (HMG-Co A) reductase inhibitors, ie, the statins.[@b7-vhrm-7-333] Recently, many statins have been used for their overall antihypercholesterolemic action in patients with atherosclerosis. They are presumed to work by upregulating the LDL receptor, thereby lowering LDL cholesterol in particular. In addition to lowering cholesterol levels, statins seem to act on the formation and progression of atherosclerotic plaque through alternative mechanisms involved in progression of the disease.[@b8-vhrm-7-333] The various statins differ in their pharmacokinetics, therapeutic efficacy, drug interactions, dosage, and administration, and therefore they differ in their potential advantages and disadvantages. Reduction of lipid peroxidation may be one of the important features explaining the favorable effect of statins in preventing or reducing atherosclerosis. Even though some investigators have shown the antioxidant potential of statins in vitro,[@b8-vhrm-7-333] in vitro investigations may not be the best approach to evaluate the effects of these agents because many other relevant events may be taking place in vivo.

In this study, we examined lipid peroxidation products, ie, thiobarbituric acid reactive substances (TBARS) and LDL-conjugated diene, formed as a result of oxidative stress generated in a hypercholesterolemic atherosclerosis model in rabbits. The antioxidant activity of defensive enzymes, including superoxide dismutase, catalase, and paraoxonase, was also investigated to determine oxidative status. The effects of atorvastatin, a potent HMG-Co A reductase inhibitor, with the longest half-life of its group, was evaluated for its influence on lipid profiles, lipid peroxidation, and the antioxidant system, as well as its impact on paraoxonase activity. In addition, atherosclerotic plaque formation and the outcome of atorvastatin treatment was assessed histopathologically.

Methods
=======

Animal model
------------

Forty male New Zealand rabbits weighing 2.5--3.5 kg were used for the hypercholesterolemic animal model. The study protocol was reviewed and approved by the ethics committee of the Ege University Medical School. All the animals were housed in individual cages and were quarantined for 7 days prior to the study, and received standard pellets (15% protein, 2.5% lipid, 15% cellulose, 14% clay, 13% water) during this time. The rabbits were then divided into four groups: Group 1, which received standard pellets of 100 g/kg/day for 15 weeks (controls, n = 11); Group 2, which received standard pellets for 15 weeks, with atorvastatin 5 mg/kg/day added from week 7 and continued until the end of week 15 (atorvastatin group, n = 10); Group 3, which received an atherogenic diet (100 g/kg/day, 2% cholesterol, 1.5% butter added to standard pellets) for 15 weeks (atherogenic diet group, n = 9); and Group 4, which received an atherogenic diet with atorvastatin added from week 7 until the end of week 15 (atherogenic diet + atorvastatin group, n = 10). Blood samples were collected from the ear veins of all rabbits at baseline, at week 7 just before starting atorvastatin treatment, and at the end of the study at week 15. All blood samples were obtained after an overnight fast, and all serum and plasma was immediately separated. All animals were sacrificed using an overdose of pentobarbital. The study and its design were approved by the local ethics and research committee of Ege University, Faculty of Medicine.

Serum analysis
--------------

Serum samples were stored at −80°C until analysis. Serum paraoxonase activity was measured using the synthetic substrate, paraoxon (diethyl-*ρ*-nitrophenyl phosphate). Paraoxonase activity towards paraoxon was assessed by measuring liberation *of ρ*-nitrophenol. The *ρ*-nitrophenol production rate at 405 nm was recorded for 2.5 minutes at 15-second intervals. Other serum parameters, ie, total cholesterol, triglyceride, high-density lipoprotein (HDL) cholesterol and LDL cholesterol, were determined by routine commercial kits (Randox Laboratories Ltd, County Antrim, Ireland).

Erythrocyte analysis
--------------------

After separation of plasma, the packed erythrocytes were washed twice with 9 g/L NaCl solution and hemolyzed with ice-cold water (1/5, v/v). Superoxide dismutase activity and catalase activity were determined immediately in the hemolysates. Hemoglobin values were measured by Drabkin's method.[@b9-vhrm-7-333]

Superoxide dismutase activity was measured spectrophotometrically based on the inhibition of epinephrine auto-oxidation by superoxide dismutase at 480 nm as described by Sozmen et al, using a Shimadzu UV-120 spectrophotometer (Kyoto, Japan). The assay was calibrated using purified superoxide dismutase, and 1 unit of enzyme was defined as the amount that inhibits 50% of auto-oxidation of epinephrine.[@b10-vhrm-7-333]

Catalase activity was determined as described by Aebi.[@b11-vhrm-7-333] The degradation of hydrogen peroxide (H~2~O~2~) by the catalase enzyme was recorded spectrophotometrically at 240 nm. One unit of catalase was defined as the amount of enzyme that decomposes 1 μmol H~2~O~2~/minute under specific conditions.

For measurement of TBARS levels, thiobarbituric acid 0.12 M in trichloroacetic acid 15% and HCl 1% was added to the hemolysates and boiled at 100°C for 20 minutes. After centrifugation at 2000 rpm for 10 minutes, absorbance of the supernatant at 532 nm was measured spectrophotometrically. The results were calculated as nmol/mL with respect to standards prepared with 1,1,3,3-tetraetoxypropane. The results are given as nmol/g of hemoglobin.

LDL isolation and in vitro oxidation
------------------------------------

Plasma samples were incubated at room temperature for 30 minutes with a commercial precipitant reagent (Merck, Darmstadt, Germany), as suggested by Taus et al.[@b12-vhrm-7-333] After centrifugation at 1600 *g* for 10 minutes, LDL samples were solubilized using sodium hydroxide 0.15 M. LDL oxidation was assessed by TBARS and LDL-conjugated diene levels in LDL samples containing 200 μg of protein. LDL oxidation was monitored at 234 nm with a Shimadzu UV-120 spectrophotometer, and the calculations were performed using an extinction coefficient of 29,500 L/mol/cm.

In vitro oxidation of LDL was induced by incubating the isolated lipoproteins with copper sulfate (CuSO~4~) 5 μM, and LDL-conjugated diene formation was analyzed by monitoring the absorbance change at 234 nm over 3 hours at 5-minute intervals. The peak of diene conjugation was observed and assessed at minute 110 after stimulation of in vitro oxidation of LDL (sLDL diene) with CuSO~4~. TBARS levels (sLDL TBARS) were also determined at this point. Protein measurements were performed according to Lowry's method.[@b13-vhrm-7-333]

Tissue analysis
---------------

Arcus aortic tissues were removed and washed in saline. For the biochemical assays, aortic tissues were homogenized in ice-cold phosphate buffer and centrifuged at 2000 *g* for 10 minutes. Superoxide dismutase and catalase assays were done, as described for the hemolysate measurements.

Malondialdehyde levels were measured using a commercial kit (LPO-586; Oxis Research, Beverly Hills, CA). The assay is based on a chromogenic reaction, ie, N-methyl-2-phenylindole with malondialdehyde. The results were calculated as nmol/g protein with respect to the calibration curve prepared with 1,1,3,3-tetraethoxypropane.

The arcus aortic tissues were fixed with formaldehyde 10% for histopathological examination. After fixation, the arteries were embedded in paraffin and cross-sectioned into slices of 4--5 μm thickness at 5 mm intervals. The cross-sections of aortic tissue were stained with hematoxylin and eosin, and examined using an Olympus BH-2 light microscope (Tokyo, Japan).

Statistical analysis
--------------------

Statistical analyses were performed using the statistical SPSS package program for Windows, (v 11; SPSS Inc, Chicago, IL). Comparisons of parameters between the different groups were done using the nonparametric Mann--Whitney U test. Statistical evaluations within the groups were done using the Wilcoxon signed-rank test. *P* \< 0.05 was considered to indicate a statistically significant difference for both tests.

Results
=======

Lipid profile
-------------

As expected, the atherogenic diet caused a pronounced increase in all lipid fractions (*P* \< 0.01, [Table 1](#t1-vhrm-7-333){ref-type="table"}). Atorvastatin treatment achieved a significant 32.7% decrease (*P* \< 0.01) in total cholesterol, a 25.5% decrease (*P* \< 0.01) in LDL cholesterol, and a 14% decrease in HDL cholesterol (*P* \< 0.01) in Group 4. In our model, treatment with atorvastatin did not cause a significant change in triglyceride levels.

Oxidative status of erythrocytes
--------------------------------

Analysis at week 7 showed that the atherogenic diet caused a significant increase (*P* \< 0.01) in superoxide dismutase and catalase activity in Group 3 and Group 4 compared with basal levels ([Table 2](#t2-vhrm-7-333){ref-type="table"}). The atherogenic diet for 7 weeks doubled the TBARS levels (*P* \< 0.01) in Group 3 and Group 4. While treatment with atorvastatin led to a significant decrease in superoxide dismutase activity (*P* \< 0.05) and TBARS levels (*P* \< 0.05), it had no significant effect on catalase activity in Group 4. Comparison of superoxide dismutase levels in the second and final blood samples indicated that the superoxide dismutase levels in Group 3 (atherogenic diet without treatment) continued to increase in the second half of the experiment but the increase was not statistically significant. Even though catalase activity was modified by atorvastatin treatment, the change was not statistically significant, in contrast with superoxide dismutase activity ([Table 2](#t2-vhrm-7-333){ref-type="table"}).

LDL oxidation and paraoxonase
-----------------------------

TBARS and LDL-conjugated diene levels are shown in [Figure 1](#f1-vhrm-7-333){ref-type="fig"}. Basal levels were measured at 0 minutes (bLDL TBARS and bLDL diene) before induction of Cu^2+^ oxidation, and stimulated levels were measured at minute 110 (sLDL TBARS and sLDL diene) after induction of oxidation.

The baseline blood samples showed no difference between the groups for LDL diene and TBARS levels. The atherogenic diet (Group 3 and Group 4) caused a pronounced increase in both basal and Cu^2+^-stimulated LDL-conjugated diene levels (*P* \< 0.01, [Figure 1A](#f1-vhrm-7-333){ref-type="fig"}). bLDL TBARS levels after 7 weeks of the atherogenic diet showed no significant difference, but Cu^2+^-stimulated sLDL TBARS levels at 110 minutes for both atherogenic diet groups were significantly higher than for the normal diet groups (*P* \< 0.01, [Figure 1B](#f1-vhrm-7-333){ref-type="fig"}).

Eight weeks of treatment with atorvastatin significantly decreased both sLDL TBARS levels (25.3%, *P* \< 0.05) and sLDL-conjugated diene levels (25.5%, *P* \< 0.01) in Group 4 in comparison with the atherogenic diet group not receiving atorvastatin treatment (Group 3). There was a significant difference between the results for the atherogenic diet groups with and without atorvastatin treatment (Group 3 and Group 4, respectively) for LDL TBARS (*P* \<0.01) and LDL-conjugated diene levels (*P* \<0.05, [Figures 1A](#f1-vhrm-7-333){ref-type="fig"} and [1B](#f1-vhrm-7-333){ref-type="fig"}).

As shown in [Figure 2](#f2-vhrm-7-333){ref-type="fig"}, paraoxonase activity in all groups showed no difference at baseline. In the second blood samples taken at week 7, paraoxonase activity in the atherogenic diet groups (Group 3 and Group 4) was significantly lower than in the normal diet groups (Group 1 and Group 2, *P* \< 0.01). Evaluation within the same groups showed that the atherogenic diet decreased paraoxonase activity significantly (*P* \< 0.01). Atorvastatin treatment caused an increase in paraoxonase activity in Group 4 (*P* \< 0.01), but this increase was not statistically significant in comparison with untreated hypercholesterolemic rabbits in Group 3.

Oxidant--antioxidant status in aortic tissue
--------------------------------------------

Superoxide dismutase activity in the arcus aortic tissues from the atherogenic diet group was significantly higher than in the control group (*P* \< 0.01, [Figure 3](#f3-vhrm-7-333){ref-type="fig"}). Superoxide dismutase activity in Group 4 was as low as in the control group. Superoxide dismutase and catalase activity in aortic tissue did not show any significant difference between the treatment groups. Malondialdehyde levels in the aortic tissues of the atherogenic diet group was significantly higher than in the control group (*P* \< 0.01), and atorvastatin treatment lowered malondialdehyde levels to basal values ([Figure 3](#f3-vhrm-7-333){ref-type="fig"}).

Histopathological examination of arcus aortic tissue
----------------------------------------------------

Histological sections of arcus aortic tissue were stained with hematoxylin and eosin and examined microscopically. The microscopic images of the arcus aortic sections of the normal diet groups appeared normal, with organized intimal surfaces ([Figure 4A](#f4-vhrm-7-333){ref-type="fig"}). In the microscopic images obtained for arcus aortic sections from the hypercholesterolemic group without any treatment (Group 3), thick atherosclerotic plaques were observed surrounding the intima, and the arterial lumina were visibly obstructed by these plaques. Leukocyte infiltrations were noticeable in the intima of these specimens ([Figures 4B](#f4-vhrm-7-333){ref-type="fig"} and [4C](#f4-vhrm-7-333){ref-type="fig"}). In Group 4, which received atorvastatin treatment, it was observed that plaque formation was totally or partially repressed, and significantly localized ([Figures 4D](#f4-vhrm-7-333){ref-type="fig"}, [4E](#f4-vhrm-7-333){ref-type="fig"}, and [4F](#f4-vhrm-7-333){ref-type="fig"}).

Discussion
==========

Even though atherosclerosis is a complex, progressive, and multifactorial disease, nowadays there is no doubt that elevated plasma cholesterol levels play a dominant role in its pathogenesis. HMG-CoA reductase inhibitors, ie, statins, are widely prescribed in many countries to lower cholesterol levels in patients at risk.[@b14-vhrm-7-333] In this study, we investigated the effect of atorvastatin on the oxidant--antioxidant status of LDL cholesterol and erythrocytes, as well as in arcus aortic tissue.

In the animal model used, an atherogenic diet severely increased cholesterol levels ([Table 1](#t1-vhrm-7-333){ref-type="table"}). Plasma total cholesterol and LDL cholesterol levels reached about 20 times the initial values, consistent with the results of another study reported by Bustos et al.[@b15-vhrm-7-333] The increase in triglyceride levels may have been associated with the addition of butter to the atherogenic diet.

Besides being a potent HMG-CoA reductase inhibitor, atorvastatin also has the longest half-life among the available statins, which contributes to its high efficacy. In view of this and conflicting reports about the antioxidant characteristics of the drug, atorvastatin was chosen from the available statins for this study. The dose of atorvastatin used (5 mg/kg/day) was decided on the basis of previous experiments using 1, 2.5, and 10 mg/kg/day.[@b15-vhrm-7-333]

It must be emphasized that, in contrast with other studies, we did not start atorvastatin treatment at the beginning of the experiment, but started it after 7 weeks of the atherogenic diet, in order to mimic conditions of human atherosclerosis, where statins are used in most cases after atherogenesis is established. Most studies in humans are performed after the onset of clinical signs when the disease is well advanced. In this respect, animal models are more convenient to use because they allow study of the initiation and progression of the preclinical stages of atherosclerosis in a more controlled setting within a shorter period of time. As expected, atorvastatin achieved a 25% decrease in LDL cholesterol levels, consistent with previous studies.[@b15-vhrm-7-333]--[@b17-vhrm-7-333]

LDL levels in the atherogenic diet group were higher than in the control group in spite of treatment with atorvastatin, probably due to the excessive amount of cholesterol added to the diet. However, this gave us the opportunity to examine and compare the beneficial effects of atorvastatin additional to lowering of cholesterol levels.

Erythrocytes are a very appropriate medium via which cholesterol can exert a pro-oxidant action due to the potential for free radical generation. Therefore, in this study, oxidant status was studied in erythrocytes[@b18-vhrm-7-333],[@b19-vhrm-7-333] as well as in LDL fractions. Our results show that an atherogenic diet caused a prominent increase in superoxide dismutase and catalase antioxidant activity and also in TBARS levels ([Table 2](#t2-vhrm-7-333){ref-type="table"}). The increase in superoxide dismutase activity represents an important physiological adaptation counteracting the increase in oxidative stress.[@b19-vhrm-7-333] The enhanced levels of TBARS are also an indicator of the oxidant stress induced by hypercholesterolemia. In this study, the increase in TBARS levels in spite of enhanced superoxide dismutase activity suggests that the elevation in superoxide dismutase activity was inadequate for complete prevention of lipid peroxidation in the hypercholesterolemic group. The significant decrease in superoxide dismutase activity in erythrocytes and changes in TBARS levels after 8 weeks of atorvastatin treatment, indicate the antioxidant effect of the drug, in support of previous studies.[@b20-vhrm-7-333],[@b21-vhrm-7-333]

Wassmann et al[@b22-vhrm-7-333] reported increased catalase protein expression and enzyme activity following upregulation of catalase mRNA, with no significant alteration in mRNA expression of superoxide dismutase in vascular smooth muscle cells in vitro. In the same study, while atorvastatin did not have any significant effect on vascular mRNA expression of superoxide dismutase, vascular catalase mRNA expression was increased in the aortic tissue of hypertensive rats treated with atorvastatin in comparison with controls. In the present study, the changes in superoxide dismutase and catalase activity coincide with the in vivo results of the study reported by Wassmann et al. The more distinctive changes in superoxide dismutase activity than in catalase activity may be due to the different animal models used.

Atorvastatin and its metabolites formed in in vivo circumstances may prevent enhancement of the hydroxyl and peroxyl radicals generated by hypercholesterolemia, probably via their radical scavenging, metal-chelating capacity, and the attenuating effect on output of superoxide anions.

In this study, LDL TBARS and LDL-conjugated diene levels were measured at baseline and after induction of oxidation using Cu^2+^ to evaluate the oxidation status of LDL. The significant increase in LDL TBARS and LDL-conjugated diene levels in the hypercholesterolemic rabbits represents the effect of hypercholesterolemia on the oxidative modification of LDL, probably via increased susceptibility to oxidation.[@b2-vhrm-7-333]

The results of this study demonstrate the success of atorvastatin therapy in alleviating the production of LDL TBARS and LDL-conjugated diene. The oxidatively modified lipids and their degradation products are believed to have proinflammatory, immunogenic, and cytotoxic properties which contribute to both the initiation and progression of atherosclerotic lesions. It is reported that products of oxidatively modified LDL contribute to recruitment of monocytes and T cells, directly or indirectly, via induction of chemokines and endothelial cell adhesion molecules.[@b2-vhrm-7-333] The present study supports this hypothesis, with histopathological examination showing atherosclerotic plaque formation and nearly 50% luminal narrowing ([Figures 1A](#f1-vhrm-7-333){ref-type="fig"} and [1B](#f1-vhrm-7-333){ref-type="fig"}) in aortic tissue from the nontreated atherogenic diet group.

There is no doubt that statins have a positive effect on regulation of total cholesterol and LDL cholesterol levels. Some authors have suggested that inhibition of LDL oxidation by statins may be independent of any lipid-lowering effects.[@b23-vhrm-7-333] According to earlier studies, statins were assumed to reduce susceptibility of LDL to in vitro oxidation.[@b24-vhrm-7-333] It has been suggested that the inhibitory effect of statins on LDL oxidation may result from enhanced removal from plasma of "aged" LDL, which is more prone to oxidation than newly synthesized LDL. This effect could be due to statin-induced stimulation of LDL receptor activity in liver cells and to the inhibition of very low-density LDL (VLDL) and LDL production in the liver.[@b25-vhrm-7-333] However, a few studies have reported that, with the exception of fluvastatin, none of the parent forms of the hypolipidemic drugs studied demonstrated a direct inhibitory antioxidant effect on LDL oxidation.[@b26-vhrm-7-333]

Singh et al reported that atorvastatin therapy had a dose-response effect with regard to decreasing oxidized LDL. They also reported other pleiotropic effects of the drug, evidenced by a significant decrease in related inflammatory markers, including high sensitivity C-reactive protein, matrix metalloproteinase-9, and NF-κB activity, especially at high doses, ie, 80 mg/day.[@b27-vhrm-7-333] Aviram et al reported that atorvastatin did not affect oxidation of LDL in vitro, even at high concentrations.[@b20-vhrm-7-333] However, low pharmacological concentrations of specific hydroxylated metabolites of the drug demonstrated a very potent inhibitory effect on LDL, VLDL, and HDL oxidation, both in metal ion-dependent and metal ion-independent systems. The molecular structure of atorvastatin hydroxymetabolites enables them to act as electron donors and, hence, as potent antioxidants.[@b20-vhrm-7-333] Therefore, it may be proposed that even if the parent drug does not show antioxidant properties, its metabolites may have antioxidant activity in vivo. This may be the reason for the conflicting data generated by in vivo and ex vivo studies.

The scientific debate continues on how HDL exerts its protective effect against atherosclerosis. Until recently, the focus of attention was on the role of HDL in reverse cholesterol transport. The human serum paraoxonase 1 enzyme might be one of the ways in which HDL exerts its antiatherogenic action.[@b28-vhrm-7-333],[@b29-vhrm-7-333] Serum paraoxonase 1 is a 45 kDa glycoprotein which is tightly bound to HDL sub-fractions containing apolipoprotein A-I and apolipoprotein J (clusterin).[@b30-vhrm-7-333] Paraoxonase 1 hydrolyzes aromatic carboxylic acid esters, organophosphates, carbamates, and lactones, and acts to protect LDL against oxidative modification, thereby exhibiting anti-atherogenic and anti-inflammatory effects.[@b29-vhrm-7-333] This proposal is based on the studies of Aviram and Mackness who showed that in vitro supplementation of human HDL or whole serum with purified paraoxonase 1 significantly inhibited Cu^2+^-induced lipoprotein oxidation in a concentration-dependent manner.[@b28-vhrm-7-333],[@b31-vhrm-7-333],[@b32-vhrm-7-333] The results of the present study show that an atherogenic diet results in a sharp decrease in paraoxonase activity, leading to loss of another guardian against oxidation and atherosclerosis. The inadequate paraoxonase activity seen in the atherogenic diet groups in this study probably contributes to the increased levels of oxidation markers (TBARS, oxidized LDL, LDL-conjugated dienes). The low paraoxonase activity observed in the atherogenic diet groups is consistent with the results of other research.[@b32-vhrm-7-333]

Loss of antioxidant paraoxonase activity from HDL or repressed expression of the enzyme may explain the decrease in paraoxonase activity seen with an atherogenic diet. In this study, although paraoxonase activity was studied, paraoxonase mass or expression was not assayed, so more detailed information will have to come from further studies.

Leitinger et al reported that an atherogenic diet resulted in the formation of oxidized phospholipids in livers of mice rendered genetically susceptible to diet-induced atherosclerosis.[@b34-vhrm-7-333] These oxidized phospholipids are believed to induce an acute-phase response which results in production of proinflammatory HDL susceptible to atherosclerosis.[@b34-vhrm-7-333] LDL-derived oxidized phospholipids were found to induce interleukin-6 in hepatocytes and to repress paraoxonase mRNA levels. In humans, paraoxonase 1 activity and serum HDL susceptibility to oxidation are reported to be inversely related in several groups of patients with increased risk for atherosclerosis, such as those with hypercholesterolemia, noninsulin-dependent diabetes, or vascular disease.[@b32-vhrm-7-333],[@b35-vhrm-7-333],[@b36-vhrm-7-333]

Superoxide dismutase and catalase activity and malondialdehyde levels in aortic tissue gave us the chance to compare and evaluate oxidant status in aortic tissues from different groups ([Figure 3](#f3-vhrm-7-333){ref-type="fig"}). The results obtained coincide with the findings for LDL fractions and erythrocytes. Superoxide dismutase activity in the aortic tissue from the atherogenic diet group was significantly higher than in Group 1 controls. Superoxide dismutase activity in Group 4 rabbits receiving statin treatment with an atherogenic diet was as low as in Group 1 controls. Catalase activity in the same tissues did not show any statistically significant difference between groups, even though there was a slight increase of activity in the atherogenic diet group. These results can be explained as a collaborative interplay for defense against the rise of free oxygen radicals.[@b18-vhrm-7-333] Lipid peroxidation and aortic antioxidant defense mechanisms take action before the formation of gross lipid infiltration in the vessels of animals receiving an atherogenic diet, and some antioxidant mechanisms may act more prominently than others during this interplay.[@b37-vhrm-7-333] Other studies have also demonstrated significantly increased enzymatic activity and protein expression of superoxide dismutase in macrophage-rich atherosclerotic lesions in accordance with our data.[@b38-vhrm-7-333],[@b39-vhrm-7-333] The vessel wall being 100-fold richer than the other tissues for extracellular superoxide dismutase activity may also be the reason why the changes in the superoxide dismutase activity both in hypercholesterolemia and atorvastatin treatment were more expressive than the catalase activity observed in the aortic tissue.[@b40-vhrm-7-333] Malondialdehyde levels showed a two-fold increase in the atherogenic diet group in comparison with controls, and atorvastatin therapy lowered the levels of malondialdehyde to a point even lower than the control group. The aortic tissue probably was the best medium for atorvastatin to show its antioxidant and antiatherosclerotic effects, which are clearly shown by the oxidant status markers and histopathological data ([Figure 4](#f4-vhrm-7-333){ref-type="fig"}). The reason for this is probably because atherosclerosis is a complex and miscellaneous disease, and atorvastatin not only has a favorable influence on oxidation and lipid profiles, but also exhibits pleiotropic effects on inflammation, macrophage accumulation, and even the calcification phases the atherosclerotic plaque goes through.[@b27-vhrm-7-333],[@b41-vhrm-7-333]--[@b44-vhrm-7-333] Reflecting the summation of all these effects of atorvastatin, aortic tissue was the best medium through which to observe the outcome of treatment.

Even though animal studies are very valuable, some mechanisms may differ from those in humans, and this may be one of the limitations of this study. Another limitation was that the animals did not undergo angiography. However, the histological data obtained at the end of the experiment could not have been obtained in human patients, and that is an advantage of the present study and similar studies carried out using animal models.

Conclusion
==========

The benefit of atorvastatin therapy certainly appears to exceed the cholesterol-lowering effects of the statins, and this study provides evidence that atorvastatin has an anti-atherogenic effect in a primary prevention setting, not just by decreasing lipid levels, but also by suppressing oxidation of LDL. The beneficial effect of atorvastatin on oxidative status seems to be one of its most important benefits, ie, a preventative effect on plaque formation.

Despite the discussion on the widespread use of statins and at what point their use is essential, the present study shows that atorvastatin has a dramatic anti-atherosclerotic effect, and part of this effect seems to be due to the anti-oxidant features of the parent drug and/or its metabolites, favoring inhibition of LDL oxidation in addition to its other pleiotropic effects. We believe comprehending the entire spectrum of benefits associated with atorvastatin therapy would allow better therapeutic application and foster the early and appropriate use of a statin.
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![**A**) 0 minutes (basal) and 110 minutes (after induction of oxidation with Cu^2+^) values of LDL-conjugated diene and **B**) LDL TBARS levels of all groups by the time of the experiment.\
**Notes: \****P* \< 0.01, Mann--Whitney U test vs Group 1 (controls); ^○^*P* \< 0.01, Wilcoxon signed-rank test; comparison of values before and after atorvastatin treatment within the group.\
**Abbreviations:** LDL, low-density lipoprotein; TBARS, thiobarbituric acid reactive substances.](vhrm-7-333f1){#f1-vhrm-7-333}

![Serum paraoxonase activities in the first blood samples at the beginning of the experiment, the second blood samples taken at the end of week 7 after application of different diet protocols specific to each group, and the third blood samples taken after atorvastatin treatment.\
**Notes: \****P* \< 0.01, Mann--Whitney U test vs Group 1 (controls); ^○^*P* \< 0.01, Wilcoxon signed-rank test vs baseline.\
**Abbreviation:** PON, paraoxonase.](vhrm-7-333f2){#f2-vhrm-7-333}

![**A**) Superoxide dismutase activity, **B**) catalase activity, **C**) malondialdehyde levels in the arcus aorta tissue of different groups of subjects.\
**Notes:** ^a^*P* \< 0.01, by Mann--Whitney U test vs Group 1 (control); ^b^*P* \< 0.01, by Mann--Whitney U test vs Group 2; ^c^*P* \< 0.01 by Mann--Whitney U test vs Group 3 and Group 4 (effect of atorvastatin treatment).\
**Abbreviations:** SOD, superoxide dismutase; MDA, malondialdehyde.](vhrm-7-333f3){#f3-vhrm-7-333}

![Histological images of arcus aorta tissues of different groups. **A**) Group 1, normal diet, normal epithelial and intimal lamina; **B**, **C**) Group 3, hypercholesterolemic diet and with huge atherosclerotic plaques surrounding the lumen; **D**--**F**) Group 4, hypercholesterolemic diet and atorvastatin treatment, with thin and limited atherosclerotic plaque formation.](vhrm-7-333f4){#f4-vhrm-7-333}

###### 

Serum total cholesterol, LDL cholesterol, HDL cholesterol, and triglyceride levels throughout the experiment

  **Median/percentile (10%--90%)**   **Group 1 Normal diet (n = 11)**   **Group 2 Normal diet + atorvastatin (n = 10)**                                                      **Group 3 Hypercholesterolemic diet (n = 9)**                                                                                                         **Group 4 Hypercholesterolemic diet + atorvastatin (n = 10)**
  ---------------------------------- ---------------------------------- ---------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **TC (mg/dL)**                                                                                                                                                                                                                                                                                                                   
  0                                  110 (91--137)                      116 (90--141)                                                                                        116 (72--144)                                                                                                                                         113 (89--149)
  Week 7                             114 (87--141)                      117 (78--133)                                                                                        1841^[a](#tfn2-vhrm-7-333){ref-type="table-fn"},[b](#tfn3-vhrm-7-333){ref-type="table-fn"},[x](#tfn6-vhrm-7-333){ref-type="table-fn"}^ (1111--2599)   1687^[a](#tfn2-vhrm-7-333){ref-type="table-fn"},[b](#tfn3-vhrm-7-333){ref-type="table-fn"},[x](#tfn6-vhrm-7-333){ref-type="table-fn"}^ (1112--2142)
  Week 15                            111 (89--137)                      92 (67--105)                                                                                         2015^[a](#tfn2-vhrm-7-333){ref-type="table-fn"},[b](#tfn3-vhrm-7-333){ref-type="table-fn"},[x](#tfn6-vhrm-7-333){ref-type="table-fn"}^ (1097--2913)   1135^[a](#tfn2-vhrm-7-333){ref-type="table-fn"},[b](#tfn3-vhrm-7-333){ref-type="table-fn"},[c](#tfn4-vhrm-7-333){ref-type="table-fn"},[x](#tfn6-vhrm-7-333){ref-type="table-fn"},[y](#tfn8-vhrm-7-333){ref-type="table-fn"}^ (975--1365)
  **LDL (mg/dL)**                                                                                                                                                                                                                                                                                                                  
  0                                  70 (51--102)                       77 (36--86)                                                                                          72 (25--100)                                                                                                                                          56 (43--97)
  Week 7                             78 (58--99)                        73 (36--97)                                                                                          1658^[a](#tfn2-vhrm-7-333){ref-type="table-fn"},[b](#tfn3-vhrm-7-333){ref-type="table-fn"},[x](#tfn6-vhrm-7-333){ref-type="table-fn"}^ (1002--2420)   1517^[a](#tfn2-vhrm-7-333){ref-type="table-fn"},[b](#tfn3-vhrm-7-333){ref-type="table-fn"},[x](#tfn6-vhrm-7-333){ref-type="table-fn"}^ (955--1936)
  Week 15                            63 (46--95)                        49^[ϕ](#tfn7-vhrm-7-333){ref-type="table-fn"},[y](#tfn8-vhrm-7-333){ref-type="table-fn"}^ (21--82)   1807^[a](#tfn2-vhrm-7-333){ref-type="table-fn"},[b](#tfn3-vhrm-7-333){ref-type="table-fn"},[x](#tfn6-vhrm-7-333){ref-type="table-fn"}^ (857--2658)    1130^[a](#tfn2-vhrm-7-333){ref-type="table-fn"},[b](#tfn3-vhrm-7-333){ref-type="table-fn"},[ɛ](#tfn5-vhrm-7-333){ref-type="table-fn"},[x](#tfn6-vhrm-7-333){ref-type="table-fn"},[γ](#tfn9-vhrm-7-333){ref-type="table-fn"}^ (739--1507)
  **HDL (mg/dL)**                                                                                                                                                                                                                                                                                                                  
  0                                  19 (14--31)                        27 (15--31)                                                                                          21 (14--27)                                                                                                                                           25 (14--33)
  Week 7                             18 (11--37)                        21 (12--30)                                                                                          121^[a](#tfn2-vhrm-7-333){ref-type="table-fn"},[b](#tfn3-vhrm-7-333){ref-type="table-fn"},[x](#tfn6-vhrm-7-333){ref-type="table-fn"}^ (28--212)       121^[a](#tfn2-vhrm-7-333){ref-type="table-fn"},[b](#tfn3-vhrm-7-333){ref-type="table-fn"},[x](#tfn6-vhrm-7-333){ref-type="table-fn"}^ (113--188)
  Week 15                            20 (13--35)                        20[^x^](#tfn6-vhrm-7-333){ref-type="table-fn"} (11--25)                                              132^[a](#tfn2-vhrm-7-333){ref-type="table-fn"},[b](#tfn3-vhrm-7-333){ref-type="table-fn"},[x](#tfn6-vhrm-7-333){ref-type="table-fn"}^ (82--217)       104^[a](#tfn2-vhrm-7-333){ref-type="table-fn"},[b](#tfn3-vhrm-7-333){ref-type="table-fn"},[x](#tfn6-vhrm-7-333){ref-type="table-fn"},[y](#tfn8-vhrm-7-333){ref-type="table-fn"}^ (91--181)
  **Triglycerides (mg/dL)**                                                                                                                                                                                                                                                                                                        
  0                                  105 (20--171)                      98 (47--228)                                                                                         104 (94--166)                                                                                                                                         109 (97--159)
  Week 7                             112 (64--194)                      116 (49--222)                                                                                        261^[a](#tfn2-vhrm-7-333){ref-type="table-fn"},[b](#tfn3-vhrm-7-333){ref-type="table-fn"},[x](#tfn6-vhrm-7-333){ref-type="table-fn"}^ (113--482)      357^[a](#tfn2-vhrm-7-333){ref-type="table-fn"},[b](#tfn3-vhrm-7-333){ref-type="table-fn"},[x](#tfn6-vhrm-7-333){ref-type="table-fn"}^ (193--432)
  Week 15                            124 (71--282)                      67 (46--285)                                                                                         287^[a](#tfn2-vhrm-7-333){ref-type="table-fn"},[b](#tfn3-vhrm-7-333){ref-type="table-fn"},[x](#tfn6-vhrm-7-333){ref-type="table-fn"}^ (191--450)      362^[a](#tfn2-vhrm-7-333){ref-type="table-fn"},[b](#tfn3-vhrm-7-333){ref-type="table-fn"}^ (241--706)

**Notes:**

*P* \< 0.01, Mann--Whitney U test, vs Group 1 (controls);

*P* \< 0.01, Mann--Whitney U test vs Group 2;

*P* \< 0.01,

*P* \< 0,05; Mann--Whitney U test, comparison between Group 3 and Group 4 are evaluated;

*P* \< 0.01;

*P* \< 0.05, Wilcoxon signed-rank test, vs first blood samples within the same group;

P \< 0.01;

*P* \< 0.05, Wilcoxon signed-rank test vs week 7 and week 15 blood samples.

**Abbreviations:** LDL, low-density cholesterol; HDL, high-density cholesterol; TC, total cholesterol.

###### 

Erythrocyte, superoxide dismutase, and catalase activity, and TBARS levels

  **Median/percentiles (10%--90%)**   **Group 1 Normal diet (n = 11)**   **Group 2 Normal diet + atorvastatin (n = 10)**   **Group 3 Hypercholesterolemic diet (n = 9)**                                                                                                              **Group 4 Hypercholesterolemic diet + atorvastatin (n = 10)**
  ----------------------------------- ---------------------------------- ------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **eSOD (U/gHb)**                                                                                                                                                                                                                                                                    
  Start                               3333 (1965--5039)                  3064 (1537--4610)                                 2835 (1727--5423)                                                                                                                                          2984 (1274--6393)
  Week 7                              3196 (2734--4461)                  2997 (2053--4198)                                 6973^[a](#tfn12-vhrm-7-333){ref-type="table-fn"},[b](#tfn13-vhrm-7-333){ref-type="table-fn"},[d](#tfn16-vhrm-7-333){ref-type="table-fn"}^ (5478--8392)     7237^[a](#tfn12-vhrm-7-333){ref-type="table-fn"},[b](#tfn13-vhrm-7-333){ref-type="table-fn"},x^ (4011--10,259)
  Week 15                             3655 (2919--4885)                  3188 (1767--3950)                                 8101^[a](#tfn12-vhrm-7-333){ref-type="table-fn"},[b](#tfn13-vhrm-7-333){ref-type="table-fn"},[d](#tfn16-vhrm-7-333){ref-type="table-fn"}^ (4706--13,084)   5620^[a](#tfn12-vhrm-7-333){ref-type="table-fn"},[b](#tfn13-vhrm-7-333){ref-type="table-fn"},[ɛ](#tfn15-vhrm-7-333){ref-type="table-fn"},x,[γ](#tfn18-vhrm-7-333){ref-type="table-fn"}^ (3964--9325)
  **eCAT (U/g Hb)**                                                                                                                                                                                                                                                                   
  Start                               9013 (8258--12,015)                9106 (6585--12,637)                               9307 (7023--10,919)                                                                                                                                        9342 (8821--10,815)
  Week 7                              9335 (8478--10,821)                9603 (7690--12,872)                               10043^[α](#tfn13-vhrm-7-333){ref-type="table-fn"},[ϕ](#tfn17-vhrm-7-333){ref-type="table-fn"}^ (8239--18,888)                                              12245^[α](#tfn13-vhrm-7-333){ref-type="table-fn"},[ϕ](#tfn17-vhrm-7-333){ref-type="table-fn"}^ (7202--20,126)
  Week 15                             9232 (8306--11,045)                9521 (8336--11,776)                               10532^[α](#tfn13-vhrm-7-333){ref-type="table-fn"},[ϕ](#tfn17-vhrm-7-333){ref-type="table-fn"}^ (9227--17,192)                                              10531 (6523--14,025)
  **eTBARS (nmol/g Hb)**                                                                                                                                                                                                                                                              
  Start                               4210 (2948--4811)                  4365 (3444--4903)                                 3994 (3348--4973)                                                                                                                                          4537 (3180--5715)
  Week 7                              4110 (3338--5457)                  4363 (4076--5174)                                 7463^[a](#tfn12-vhrm-7-333){ref-type="table-fn"},[b](#tfn13-vhrm-7-333){ref-type="table-fn"},[d](#tfn16-vhrm-7-333){ref-type="table-fn"}^ (6515--9457)     8415^[a](#tfn12-vhrm-7-333){ref-type="table-fn"},[b](#tfn13-vhrm-7-333){ref-type="table-fn"},x^ (4607--12,748)
  Week 15                             4283 (2915--5083)                  4429 (4039--5147)                                 7035^[a](#tfn12-vhrm-7-333){ref-type="table-fn"},[b](#tfn13-vhrm-7-333){ref-type="table-fn"},[d](#tfn16-vhrm-7-333){ref-type="table-fn"}^ (6054--14,518)   6688^[a](#tfn12-vhrm-7-333){ref-type="table-fn"},[b](#tfn13-vhrm-7-333){ref-type="table-fn"},x,[γ](#tfn18-vhrm-7-333){ref-type="table-fn"}^ (4083--10,155)

**Notes:**

*P* \< 0.01;

*P* \< 0.05, Mann--Whitney U test vs Group 1 (controls);

*P* \< 0.01, Mann-Whitney U test, vs Group 2;

*P* \< 0.05, Mann--Whitney U test vs Group 3 and Group 4;

*P* \< 0.01;

*P* \< 0.05; Wilcoxon signed-rank test vs first blood samples, within the same group;

P \< 0.05; Wilcoxon signed-rank test vs second and third blood samples.

**Abbreviations:** e, erythrocyte; Hb, hemoglobin; CAT, catalase; SOD, superoxide dismutase; TBARS, thiobarbituric acid reactive substances.
